NCT01763554

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 115 (estimated)
• Sponsor: AHS Cancer Control Alberta · Academic / Other
• Sex: All
• Age: 14 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.

Conditions

• Neuroendocrine Tumors, NET

Interventions

Type	Name	Description
DRUG	Lu-177 DOTA-TATE	The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.

Timeline

• Start date: 2012-08-01
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2013-01-09
• Last updated: 2024-01-30

Locations

1 site across 1 country: Canada